Product logins

Find logins to all Clarivate products below.


Aliaksei Holik

Director for Discovery and Translational Science Consulting

Aliaksei is a biomedical scientist with over 15 years of experience in research, specializing in the use of computational biology and machine learning to unravel disease mechanisms, identify and validate therapeutic targets, and prioritize patient populations most likely to benefit from these therapies. With a strong background in Molecular Biology and Genetics, he has utilized a wide array of omics technologies throughout the entire research lifecycle, from experimental design and data generation to analysis and translating results into actionable insights.

As Director for Discovery and Translational Science Consulting Services, Aliaksei assists clients, ranging from top pharmaceutical companies to stealth-mode biotechs in their drug discovery and translational research efforts. His support encompasses data curation, management, and analytics services applied to pre-clinical and clinical datasets in order to understand disease and drug action mechanisms, prioritize targets and indications, and identify molecular and clinical biomarkers to pinpoint patient populations with the most favourable response and safety profiles.

Aliaksei holds a PhD in Cancer Biology from Cardiff University and a BSc in Molecular Biology from the University of Edinburgh.

Latest news

News June 17, 2026
Clarivate Releases Journal Citation Reports 2026

Advancing transparency and responsible journal evaluation London, U.K. June 17 2026 — Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the release of the Journal…

Partner news June 16, 2026
U.S. News Unveils 2026-2027 Best Global Universities Rankings

Universities in more than 100 countries are evaluated in the newest edition. Washington, D.C. – June 16, 2026 – U.S. News & World Report, the global authority in education rankings…

Partner news
News June 15, 2026
Clarivate’s IPfolio Selected by Mitsubishi Fuso

Managing intellectual property more efficiently with leading data and expertise London, U.K. June 15, 2026. Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that Mitsubishi…

Related resources

Three uncomfortable truths about cell and gene therapy in regulatory affairs Three uncomfortable truths about cell and gene therapy in regulatory affairs
Blog May 28, 2026
Three uncomfortable truths about cell and gene therapy in regulatory affairs
Consulting Resource Center Regulatory
How the Inflation Reduction Act could impact access to more convenient therapeutics How the Inflation Reduction Act could impact access to more convenient therapeutics
Blog February 17, 2026
How the Inflation Reduction Act could impact access to more convenient therapeutics
Biopharma Biotech Commercialization Consulting Resource Center FDA HMO Insurance Launch Managed care Market Access North America Payer Pharma pricing Route of administration U.S.
Managing uncertainty for medicine in Washington Managing uncertainty for medicine in Washington
Blog May 15, 2025
Managing uncertainty for medicine in Washington
Clinical research Early drug development research Market Access Pharma Portfolio strategy Research Research and development Research commercialization Research evaluation and management
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Blog April 2, 2025
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Market Access Pharma Portfolio strategy Regulatory Research commercialization